Hi Barbarian
for 3 x phase 2 with some decent pedigree to them, i think what we will see is a re-valuation.
The Board seems to be getting on with running the company rather than propping up the shareprice, unlike some other biotechs that receive way too much attention on HC. .
Low hanging fruit is disappearing in drug innovation, hence the stable assets like Nadolol. But CPN10 is the real jewel in the crown.
There are fundamentals at play here.
Do your own research.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.005(4.00%) |
Mkt cap ! $11.01M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.5¢ | 12.5¢ | $36.56K | 283.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 247400 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 119856 | 1 |
View Market Depth
| Last trade - 15.40pm 23/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |